Durvalumab-Associated Myocarditis Initially Presenting With Sinus Bradycardia Progressing Into Complete Heart Block

Durvalumab is a monoclonal antibody that blocks programmed cell death ligand-1 (PD-L1). It has been recently approved for the treatment of advanced urothelial and non-small cell lung cancer (NSCLC) with a more favorable side effect profile compared to traditional chemotherapy agents. We present a ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Bae, Suhwoo, Vaysblat, Michael, Ng, Jason, Beccarino, Nicholas, Makaryus, John, Sarkar, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329808/
https://www.ncbi.nlm.nih.gov/pubmed/37431327
http://dx.doi.org/10.7759/cureus.40171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329808/
https://www.ncbi.nlm.nih.gov/pubmed/37431327
http://dx.doi.org/10.7759/cureus.40171

Ejemplares similares